Journal of Clinical Oncology, Vol 19, Issue 4
(February), 2001: 1195-1206
© 2001 American Society for Clinical Oncology
Redefining the Target: Chemotherapeutics as Antiangiogenics
By Kathy D. Miller,
Christopher J. Sweeney,
George W. Sledge, Jr
From the Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN.
Address reprint requests to Kathy D. Miller, MD, 535 Barnhill Dr, RT-473, Indianapolis, IN 46202; email: kathmill{at}iupui.edu
ABSTRACT: Angiogenesis, or new blood vessel formation, is now known to play an important role in both growth and metastasis of many cancers. The central importance of angiogenesis and the understanding of how new blood vessels are formed, has led to novel therapies designed to interrupt this process. Though specific antiangiogenic compounds have only recently entered the clinic, they herald a new era, one in which biology is the basis for therapy. The intense interest in angiogenesis has also lead to a re-examination of the activity of many established cytotoxic agents. Claims of antiangiogenic activity abound, unfortunately, with no common criteria and often little evidence of clinical relevance. What are we to think? Have oncologists unknowingly been administering antiangiogenic therapy all these years? If chemotherapeutics are really antiangiogenics in disguise, why have they failed to cure most solid tumors? Might the hard-learned lessons of chemotherapy resistance pertain to the novel antiangiogenics as well? Though we can offer no certain answers to these important questions, we do offer a framework on which to order the rapidly burgeoning literature. We suggest criteria by which a cytotoxic agent might reasonably be considered to have meaningful antiangiogenic activity. Finally, we describe potential mechanisms of resistance to antiangiogenic chemotherapies—some of which may apply to the pure antiangiogenics currently in development.
This article has been cited by other articles:
|
|
|
|
 
J. H.E. Baker, J. Lam, A. H. Kyle, J. Sy, T. Oliver, S. J. Co, W. H. Dragowska, E. Ramsay, M. Anantha, T. J. Ruth, et al.
Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin
Clin. Cancer Res.,
November 15, 2008;
14(22):
7260 - 7271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. de Bazelaire, D. C. Alsop, D. George, I. Pedrosa, Y. Wang, M. D. Michaelson, and N. M. Rofsky
Magnetic Resonance Imaging-Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma
Clin. Cancer Res.,
September 1, 2008;
14(17):
5548 - 5554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Honore, A. Pagano, G. Gauthier, V. Bourgarel-Rey, P. Verdier-Pinard, K. Civiletti, A. Kruczynski, and D. Braguer
Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites
Mol. Cancer Ther.,
July 1, 2008;
7(7):
2080 - 2089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Pla, C. Grange, S. Antoniotti, C. Tomatis, A. Merlino, B. Bussolati, and L. Munaron
Arachidonic Acid-Induced Ca2+ Entry Is Involved in Early Steps of Tumor Angiogenesis
Mol. Cancer Res.,
April 1, 2008;
6(4):
535 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. O'Rourke, C. Ward, J. Worthington, J. McKenna, A. Valentine, T. Robson, D. G. Hirst, and S. R. McKeown
Evaluation of the Antiangiogenic Potential of AQ4N
Clin. Cancer Res.,
March 1, 2008;
14(5):
1502 - 1509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Garcia, H. Hirte, G. Fleming, D. Yang, D. D. Tsao-Wei, L. Roman, S. Groshen, S. Swenson, F. Markland, D. Gandara, et al.
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
J. Clin. Oncol.,
January 1, 2008;
26(1):
76 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh, E. A. Perez, T. Shenkier, D. Cella, and N. E. Davidson
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
N. Engl. J. Med.,
December 27, 2007;
357(26):
2666 - 2676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Martinez-Poveda, R. Munoz-Chapuli, S. Rodriguez-Nieto, J. M. Quintela, A. Fernandez, M.-A. Medina, and A. R. Quesada
IB05204, a dichloropyridodithienotriazine, inhibits angiogenesis in vitro and in vivo
Mol. Cancer Ther.,
October 1, 2007;
6(10):
2675 - 2685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kesari, D. Schiff, L. Doherty, D. C. Gigas, T. T. Batchelor, A. Muzikansky, A. O'Neill, J. Drappatz, A. S. Chen-Plotkin, N. Ramakrishna, et al.
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Neuro-oncol,
July 1, 2007;
9(3):
354 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Zhou, P. Guo, X. Wang, S. Nuthalapati, and J. M. Gallo
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Metronomic and Conventional Temozolomide Dosing Regimens
J. Pharmacol. Exp. Ther.,
April 1, 2007;
321(1):
265 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Buckstein, R. S. Kerbel, Y. Shaked, R. Nayar, C. Foden, R. Turner, C. R. Lee, D. Taylor, L. Zhang, S. Man, et al.
High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
September 1, 2006;
12(17):
5190 - 5198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S.W. Ng, A. Sparreboom, Y. Shaked, C. Lee, S. Man, N. Desai, P. Soon-Shiong, W. D. Figg, and R. S. Kerbel
Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel.
Clin. Cancer Res.,
July 15, 2006;
12(14):
4331 - 4338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Kogan, C. Blazquez, L. Alvarez, R. Gallily, M. Schlesinger, M. Guzman, and R. Mechoulam
A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells
Mol. Pharmacol.,
July 1, 2006;
70(1):
51 - 59.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Cassoni, T. Marrocco, B. Bussolati, E. Allia, L. Munaron, A. Sapino, and G. Bussolati
Oxytocin Induces Proliferation and Migration in Immortalized Human Dermal Microvascular Endothelial Cells and Human Breast Tumor-Derived Endothelial Cells
Mol. Cancer Res.,
June 1, 2006;
4(6):
351 - 359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Kerbel
Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Science,
May 26, 2006;
312(5777):
1171 - 1175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Franco, S. Man, L. Chen, U. Emmenegger, Y. Shaked, A. M. Cheung, A. S. Brown, D. J. Hicklin, F. S. Foster, and R. S. Kerbel
Targeted Anti-Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia.
Cancer Res.,
April 1, 2006;
66(7):
3639 - 3648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi
The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis.
Clin. Cancer Res.,
March 15, 2006;
12(6):
1839 - 1849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Yance Jr and S. M. Sagar
Targeting angiogenesis with integrative cancer therapies.
Integr Cancer Ther,
March 1, 2006;
5(1):
9 - 29.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Gandhi, D.B. Chepeha, T. Miller, R.C. Carlos, C.R. Bradford, R. Karamchandani, F. Worden, A. Eisbruch, T.N. Teknos, G.T. Wolf, et al.
Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy.
AJNR Am. J. Neuroradiol.,
January 1, 2006;
27(1):
101 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shaked, U. Emmenegger, G. Francia, L. Chen, C. R. Lee, S. Man, A. Paraghamian, Y. Ben-David, and R. S. Kerbel
Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy
Cancer Res.,
August 15, 2005;
65(16):
7045 - 7051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ma, G. Francia, A. Viloria-Petit, D. J. Hicklin, J. du Manoir, J. Rak, and R. S. Kerbel
In vitro Procoagulant Activity Induced in Endothelial Cells by Chemotherapy and Antiangiogenic Drug Combinations: Modulation by Lower-Dose Chemotherapy
Cancer Res.,
June 15, 2005;
65(12):
5365 - 5373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Herbst, A. Onn, and A. Sandler
Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications
J. Clin. Oncol.,
May 10, 2005;
23(14):
3243 - 3256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Raspollini, F. Castiglione, F. Garbini, A. Villanucci, G. Amunni, G. Baroni, V. Boddi, and G. L. Taddei
Correlation of Epidermal Growth Factor Receptor Expression with Tumor Microdensity Vessels and with Vascular Endothelial Growth Factor Expression in Ovarian Carcinoma
International Journal of Surgical Pathology,
April 1, 2005;
13(2):
135 - 142.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. P. Schneider and K. D. Miller
Angiogenesis of Breast Cancer
J. Clin. Oncol.,
March 10, 2005;
23(8):
1782 - 1790.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Hicklin and L. M. Ellis
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
J. Clin. Oncol.,
February 10, 2005;
23(5):
1011 - 1027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cristofanilli and G. N. Hortobagyi
Breast Cancer Highlights: Key Findings from the San Antonio Breast Cancer Symposium: A U.S. Perspective
Oncologist,
July 1, 2004;
9(4):
471 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Emmenegger, S. Man, Y. Shaked, G. Francia, J. W. Wong, D. J. Hicklin, and R. S. Kerbel
A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens
Cancer Res.,
June 1, 2004;
64(11):
3994 - 4000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ferrara
Vascular Endothelial Growth Factor as a Target for Anticancer Therapy
Oncologist,
June 1, 2004;
9(suppl_1):
2 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Sparano, R. Gray, B. Giantonio, P. O'Dwyer, and R. L. Comis
Evaluating Antiangiogenesis Agents in the Clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials
Clin. Cancer Res.,
February 15, 2004;
10(4):
1206 - 1211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. W. Ng, W. D. Figg, and A. Sparreboom
Taxane-Mediated Antiangiogenesis in Vitro: Influence of Formulation Vehicles and Binding Proteins
Cancer Res.,
February 1, 2004;
64(3):
821 - 824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Pastorino, C. Brignole, D. Marimpietri, M. Cilli, C. Gambini, D. Ribatti, R. Longhi, T. M. Allen, A. Corti, and M. Ponzoni
Vascular Damage and Anti-angiogenic Effects of Tumor Vessel-Targeted Liposomal Chemotherapy
Cancer Res.,
November 1, 2003;
63(21):
7400 - 7409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bocci, G. Francia, S. Man, J. Lawler, and R. S. Kerbel
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
PNAS,
October 28, 2003;
100(22):
12917 - 12922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Santos, C. Costa, S. Pereira, M. Koch, T. Amaro, F. Cardoso, T. Guimaraes, M. J. Bento, F. Lobo, S. Pinto, et al.
Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours
Ann. Onc.,
September 1, 2003;
14(9):
1419 - 1424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Garofalo, E. Naumova, L. Manenti, C. Ghilardi, G. Ghisleni, M. Caniatti, T. Colombo, J. M. Cherrington, E. Scanziani, M. I. Nicoletti, et al.
The Combination of the Tyrosine Kinase Receptor Inhibitor SU6668 with Paclitaxel Affects Ascites Formation and Tumor Spread in Ovarian Carcinoma Xenografts Growing Orthotopically
Clin. Cancer Res.,
August 1, 2003;
9(9):
3476 - 3485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Giavazzi, B. Sennino, D. Coltrini, A. Garofalo, R. Dossi, R. Ronca, M. P. M. Tosatti, and M. Presta
Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis
Am. J. Pathol.,
June 1, 2003;
162(6):
1913 - 1926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Micheletti, M. Poli, P. Borsotti, M. Martinelli, B. Imberti, G. Taraboletti, and R. Giavazzi
Vascular-targeting Activity of ZD6126, a Novel Tubulin-binding Agent
Cancer Res.,
April 1, 2003;
63(7):
1534 - 1537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Tinley, R. M. Leal, D. A. Randall-Hlubek, J. W. Cessac, L. R. Wilkens, P. N. Rao, and S. L. Mooberry
Novel 2-Methoxyestradiol Analogues with Antitumor Activity
Cancer Res.,
April 1, 2003;
63(7):
1538 - 1549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Miller, C. J. Sweeney, and G. W. Sledge
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era
Ann. Onc.,
January 1, 2003;
14(1):
20 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bocci, K. C. Nicolaou, and R. S. Kerbel
Protracted Low-Dose Effects on Human Endothelial Cell Proliferation and Survival in Vitro Reveal a Selective Antiangiogenic Window for Various Chemotherapeutic Drugs
Cancer Res.,
December 1, 2002;
62(23):
6938 - 6943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Hotchkiss, A. W. Ashton, R. Mahmood, R. G. Russell, J. A. Sparano, and E. L. Schwartz
Inhibition of Endothelial Cell Function in Vitro and Angiogenesis in Vivo by Docetaxel (Taxotere): Association with Impaired Repositioning of the Microtubule Organizing Center
Mol. Cancer Ther.,
November 1, 2002;
1(13):
1191 - 1200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A. Scappaticci
Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
J. Clin. Oncol.,
September 15, 2002;
20(18):
3906 - 3927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Conti
Vascular Endothelial Growth Factor: Regulation in the Mouse Skin Carcinogenesis Model and Use in Antiangiogenesis Cancer Therapy
Oncologist,
August 1, 2002;
7(90003):
4 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Man, G. Bocci, G. Francia, S. K. Green, S. Jothy, D. Hanahan, P. Bohlen, D. J. Hicklin, G. Bergers, and R. S. Kerbel
Antitumor Effects in Mice of Low-dose (Metronomic) Cyclophosphamide Administered Continuously through the Drinking Water
Cancer Res.,
May 1, 2002;
62(10):
2731 - 2735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tran, Z. Master, J. L. Yu, J. Rak, D. J. Dumont, and R. S. Kerbel
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
PNAS,
April 2, 2002;
99(7):
4349 - 4354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Zhang, D. Yu, D. J. Hicklin, J. A. F. Hannay, L. M. Ellis, and R. E. Pollock
Combined Anti-Fetal Liver Kinase 1 Monoclonal Antibody and Continuous Low-Dose Doxorubicin Inhibits Angiogenesis and Growth of Human Soft Tissue Sarcoma Xenografts by Induction of Endothelial Cell Apoptosis
Cancer Res.,
April 1, 2002;
62(7):
2034 - 2042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Taraboletti, G. Micheletti, M. Rieppi, M. Poli, M. Turatto, C. Rossi, P. Borsotti, P. Roccabianca, E. Scanziani, M. I. Nicoletti, et al.
Antiangiogenic and Antitumor Activity of IDN 5390, a New Taxane Derivative
Clin. Cancer Res.,
April 1, 2002;
8(4):
1182 - 1188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Marx, C. B. Steer, P. Harper, N. Pavlakis, O. Rixe, and D. Khayat
Unexpected Serious Toxicity With Chemotherapy and Antiangiogenic Combinations: Time to Take Stock!
J. Clin. Oncol.,
March 15, 2002;
20(6):
1446 - 1448.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Kerbel, G. Klement, K. I. Pritchard, and B. Kamen
Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic
Ann. Onc.,
January 19, 2002;
13(1):
12 - 15.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Klement, P. Huang, B. Mayer, S. K. Green, S. Man, P. Bohlen, D. Hicklin, and R. S. Kerbel
Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-resistant Human Breast Cancer Xenografts
Clin. Cancer Res.,
January 1, 2002;
8(1):
221 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sezer, C. Jakob, K. Niemoller, R. T.P. Poon, S.-T. Fan, and J. Wong
Angiogenesis in Cancer
J. Clin. Oncol.,
July 1, 2001;
19(13):
3299 - 3301.
[Full Text]
|
|
|
|
|
|
|
J. Tran, Z. Master, J. L. Yu, J. Rak, D. J. Dumont, and R. S. Kerbel
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
PNAS,
April 2, 2002;
99(7):
4349 - 4354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
